Boehringer Ingelheim announced new findings that further demonstrate improved lung function and asthma symptom control by adding Spiriva Respimat (tiotropium) to various patient populations with uncontrolled asthma symptoms despite the use of another daily maintenance therapy.
Two analyses in the Phase 3 clinical development program showed improved breathing in children and adolescents with moderate to severe asthma despite their allergic status.
Post hoc analyses of some Phase 3 randomized, double-blind, placebo-controlled studies showed that adding Spiriva Respimat improved peak FEV1(0–3h) and trough FEV1 across a range of baseline IgE levels and eosinophil counts, when compared to placebo. Also, adding Spiriva Respimat decreased the risk of exacerbations vs. placebo in pediatric and adolescent patients despite baseline IgE levels and eosinophil counts.
Another subgroup analysis showed that adding Spiriva Respimat effectively reduced symptoms and improved lung function in adults with mild to severe asthma across all BMI categories, including overweight or obese. Both peak FEV1(0–3h) and trough FEV1 were improved in adults with mild to severe asthma vs. placebo despite their BMI category.
Spiriva Respimat, a long-acting muscarinic antagonist (LAMA), is currently approved for use as maintenance treatment of asthma in patients aged ≥6 years. It is also indicated as long-term maintenance treatment of bronchospasm due to chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, and to reduce COPD exacerbations. It is available as 1.25mcg and 2.5mcg strength inhalation sprays containing 60 inhalations.
For more information call (800) 542-6257 or visit Spiriva.com.